These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29385930)

  • 1. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.
    Fantegrossi WE; Wilson CD; Berquist MD
    Drug Metab Rev; 2018 Feb; 50(1):65-73. PubMed ID: 29385930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effects of cannabinoids on brain neurotransmission.
    Cohen K; Weizman A; Weinstein A
    Eur J Neurosci; 2019 Aug; 50(3):2322-2345. PubMed ID: 30882962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
    Jacobson MR; Watts JJ; Boileau I; Tong J; Mizrahi R
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):330-348. PubMed ID: 30635160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.
    Stahl SM
    CNS Spectr; 2018 Jun; 23(3):187-191. PubMed ID: 29954475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cannabis and cannabinoid receptors--abuse and psychosis].
    Hjorthøj C; Nordentoft M; Fink-Jensen A
    Ugeskr Laeger; 2008 Nov; 170(46):3782-4. PubMed ID: 19014732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs of abuse and increased risk of psychosis development.
    Gururajan A; Manning EE; Klug M; van den Buuse M
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1120-35. PubMed ID: 22833579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis use and psychotic disorders: an update.
    Hall W; Degenhardt L; Teesson M
    Drug Alcohol Rev; 2004 Dec; 23(4):433-43. PubMed ID: 15763748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids and psychosis.
    Sewell RA; Ranganathan M; D'Souza DC
    Int Rev Psychiatry; 2009 Apr; 21(2):152-62. PubMed ID: 19367509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cannabis and psychosis--a review].
    Schaub M; Rössler W; Stohler R
    Praxis (Bern 1994); 2004 Jun; 93(23):997-1002. PubMed ID: 15233568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.
    Malone DT; Hill MN; Rubino T
    Br J Pharmacol; 2010 Jun; 160(3):511-22. PubMed ID: 20590561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids.
    Skryabin VY; Vinnikova MA
    J Psychiatr Pract; 2019 Nov; 25(6):485-490. PubMed ID: 31821228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis-associated psychosis: Neural substrate and clinical impact.
    Murray RM; Englund A; Abi-Dargham A; Lewis DA; Di Forti M; Davies C; Sherif M; McGuire P; D'Souza DC
    Neuropharmacology; 2017 Sep; 124():89-104. PubMed ID: 28634109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.
    Bloomfield MA; Morgan CJ; Egerton A; Kapur S; Curran HV; Howes OD
    Biol Psychiatry; 2014 Mar; 75(6):470-8. PubMed ID: 23820822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis abuse and risk for psychosis in a prodromal sample.
    Kristensen K; Cadenhead KS
    Psychiatry Res; 2007 May; 151(1-2):151-4. PubMed ID: 17383738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis and psychosis/schizophrenia: human studies.
    D'Souza DC; Sewell RA; Ranganathan M
    Eur Arch Psychiatry Clin Neurosci; 2009 Oct; 259(7):413-31. PubMed ID: 19609589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic cannabinoids as drugs of abuse.
    Ashton JC
    Curr Drug Abuse Rev; 2012 Jun; 5(2):158-68. PubMed ID: 22530798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.